Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXAMETHASONE vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Agonist at glucocorticoid receptors, leading to altered gene expression and suppression of inflammatory mediators.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Adrenal insufficiency,Inflammatory conditions,Allergic disorders,Autoimmune diseases,Cerebral edema,COVID-19 treatment (off-label),Multiple myeloma (combination therapy),Nausea/vomiting (chemotherapy-induced)
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
0.5-24 mg/day oral, IV, IM in 2-4 divided doses; anti-inflammatory: 0.75-9 mg/day; multiple myeloma: 40 mg oral/IV once daily on days 1-4, 9-12, 17-20 every 28 days.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life 3-4 hours; clinically, duration of HPA suppression may exceed 24 hours due to prolonged receptor binding.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Primarily hepatic via CYP3A4; also metabolized by 11β-HSD2 in peripheral tissues.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Primarily renal (65-80% as unchanged drug); minor biliary/fecal (<10%).
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Approximately 77% bound to albumin; minor binding to corticosteroid-binding globulin.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Vd ~0.8-1.0 L/kg; indicates extensive tissue distribution (crosses placenta, enters milk, penetrates CNS).
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral: 80-90%; IM: 80-100%; topical: negligible (systemic absorption <1% with intact skin).
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
No dose adjustment required for GFR <30 m L/min or dialysis; monitor for fluid retention.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid or use with caution, reduce dose by 75%.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
0.08-0.3 mg/kg/day oral/IV/IM in 2-4 divided doses; asthma exacerbation: 0.6 mg/kg IV/IM (max 16 mg) once; croup: 0.6 mg/kg oral/IM once.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Initiate at lowest effective dose; monitor for hyperglycemia, osteoporosis, and adrenal suppression; consider increased risk of fractures and infections.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
None required per FDA labeling.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Immunosuppression/increased infection risk,Adrenal suppression with prolonged use,Osteoporosis with long-term therapy,Hyperglycemia/diabetes exacerbation,Gastrointestinal perforation risk,Myopathy,Ocular effects (glaucoma, cataracts),Psychiatric disturbances
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Systemic fungal infections,Hypersensitivity to dexamethasone or components,Administration of live vaccines (relative contraindication),Idiopathic thrombocytopenic purpura (IM use in children)
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Limit high-sodium foods (processed snacks, canned soups) to reduce fluid retention. Avoid grapefruit and grapefruit juice as they increase dexamethasone levels via CYP3A4 inhibition. Increase potassium intake (bananas, spinach) if on loop diuretics.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
First trimester: Associated with increased risk of cleft palate (approximately 0.1-0.3% absolute risk above baseline). Second and third trimesters: May cause fetal adrenal suppression, growth restriction, and altered brain development. Chronic use increases risk of preterm birth and low birth weight.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Dexamethasone is excreted into breast milk in low concentrations (M/P ratio approximately 0.5). Doses ≤15 mg/day are generally considered compatible with breastfeeding; higher doses require monitoring for infant adrenal suppression. Avoid breastfeeding within 4 hours of oral dose.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No routine dose adjustment required; however, increased clearance in pregnancy may necessitate higher doses for desired effect (e.g., fetal lung maturation). Consider lower doses for chronic conditions due to increased sensitivity. Taper gradually to avoid adrenal crisis.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Intravenous dexamethasone causes perineal itching due to phosphate esters; warn patients. Taper after prolonged use (>3 weeks) to avoid adrenal crisis. Single dose of 10 mg may elevate INR in warfarin patients via CYP3A4 inhibition. Monitor blood glucose and potassium during therapy.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take with food or milk to reduce stomach upset.,Do not stop suddenly; follow taper schedule.,Report signs of infection (fever, sore throat) as steroid masks symptoms.,Avoid live vaccines during therapy.,Carry a steroid alert card if on long-term therapy.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
"Dexamethasone, a potent corticosteroid, induces various cytochrome P450 (CYP) enzymes, including CYP2D6, which is primarily responsible for the metabolism of atomoxetine. Concurrent use can decrease atomoxetine metabolism, leading to elevated plasma concentrations and increased risk of atomoxetine-related adverse effects such as insomnia, dry mouth, nausea, and cardiovascular effects like hypertension and tachycardia. Close monitoring for atomoxetine toxicity is warranted when dexamethasone is coadministered."
"Dexamethasone, a potent corticosteroid, induces cytochrome P450 (CYP) 3A4 enzymes, which metabolize Vincristine, a vinca alkaloid chemotherapeutic agent. This induction increases Vincristine clearance, reducing its systemic exposure and potentially compromising its antineoplastic efficacy. Clinically, this may lead to suboptimal tumor response or require dose adjustments."
"Dexamethasone, a potent glucocorticoid, induces the expression of the enzyme 24-hydroxylase (CYP24A1), which accelerates the catabolism of calcitriol (1,25-dihydroxyvitamin D3) into inactive metabolites. This reduces the bioavailability and therapeutic efficacy of calcitriol, potentially leading to inadequate control of hypocalcemia in patients with chronic kidney disease or hypoparathyroidism. Clinically, this interaction may manifest as declining serum calcium levels or worsening bone mineral density despite calcitriol therapy."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXAMETHASONE vs ABSTRAL, answered by our medical review team.
DEXAMETHASONE is a Corticosteroid that works by Agonist at glucocorticoid receptors, leading to altered gene expression and suppression of inflammatory mediators.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXAMETHASONE and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXAMETHASONE is: 0.5-24 mg/day oral, IV, IM in 2-4 divided doses; anti-inflammatory: 0.75-9 mg/day; multiple myeloma: 40 mg oral/IV once daily on days 1-4, 9-12, 17-20 every 28 days.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXAMETHASONE and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXAMETHASONE is classified as Category D/X. First trimester: Associated with increased risk of cleft palate (approximately 0.1-0.3% absolute risk above baseline). Second and third trimesters: May cause fetal adrenal suppress. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.